The Quantellect read.As of Nov 19, 2026, 6 active firms cover Vir Biotechnology Inc: 6 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $18.00 to $30.00, a moderate spread. The average target of $22.67 sits 148% above the current $9.13. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.44 next quarter toward $-2.39 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 active firms
Buy
Strong Buy00%
Buy6100%
Neutral00%
Sell00%
Strong Sell00%
Based on 6 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$22.67
+148.3% upside
Average target across 6 active firms as of Nov 19, 2026 vs $9.13 current
Highest Target$30.00
Average Target$22.67
Lowest Target$18.00
Detailed analyst forecasts for VIR
Showing 1–6 of 6 named analysts shown · 6 active firms in the rating projection
As of Nov 19, 2026, 6 of 6 active firms rate VIR a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
VIR EPS & revenue forecast
EPS · NEXT QUARTER
$-0.44
Range $-0.66 – $-0.31 · 4 analysts · -48% YoY
Next period, 4 analysts expect Vir Biotechnology Inc to earn $-0.44 a share (range $-0.66 – $-0.31), versus $-0.85 a year earlier. Full-year consensus is $-0.99, growing to $-2.39 the year after.
REVENUE · NEXT QUARTER
$17.0M
Range $500.0K – $50.0M · 4 analysts · -58732% YoY
Revenue is expected to reach $17.0M (range $500.0K – $50.0M), -58732.2% year-over-year. Full-year consensus is $330.3M, rising to $66.7M next year.
Top analysts covering Vir Biotechnology Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on VIR.
#1
Paul Choi
Goldman Sachs · Rank #110
Buy
$21.00+130.0% to target
Overall win rate
52%
+ Follow
#2
Joseph Stringer
Needham · Rank #256
Buy
$18.00+97.2% to target
Overall win rate
36%
+ Follow
#3
Patrick R. Trucchio
HC Wainwright & Co. · Rank #308
Buy
$22.00+141.0% to target
Overall win rate
36%
+ Follow
#4
Gena Wang
Barclays · Rank #410
Buy
$31.00+239.5% to target
Overall win rate
32%
+ Follow
#5
Roanna Ruiz
SVB Leerink · Rank #513
Buy
$17.00+86.2% to target
Overall win rate
30%
+ Follow
VIR stock forecast FAQ
What is VIR's average 12-month price target?+
The 6 active firms with a live target average $22.67 for Vir Biotechnology Inc over the next 12 months, ranging from a $30.00 high to a $18.00 low, as of Nov 19, 2026.
Is VIR stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 6 active firms as of Nov 19, 2026, 6 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for VIR?+
The Street-high target is $30.00 (Barclays), and the Street-low is $18.00 (Evercore ISI Group). The average of all 6 active-firm targets is $22.67.
How many active Wall Street firms cover VIR?+
6 active firms have a recognized rating on Vir Biotechnology Inc as of Nov 19, 2026, and 6 active firms carry a live 12-month price target.
Who is the most accurate analyst covering VIR?+
Among analysts who currently cover VIR, Paul Choi of Goldman Sachs has the strongest overall Quantellect track record (Rank #110). Their current call is Buy with a $21.00 target.
What is Vir Biotechnology Inc's projected EPS for next quarter?+
The consensus estimate is $-0.44 per share (range $-0.66 – $-0.31) across 4 analysts. Full-year EPS is projected at $-0.99, rising to $-2.39 the following year.
How much revenue is Vir Biotechnology Inc expected to report next quarter?+
Consensus revenue is $17.0M (range $500.0K – $50.0M). Full-year revenue is projected at $330.3M, growing to $66.7M next year.
Have analysts been upgrading or downgrading VIR lately?+
As of Nov 19, 2026, 6 of 6 active firms rate VIR a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their VIR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.